Cargando…

Predictive value of TCR Vβ-Jβ profile for adjuvant gefitinib in EGFR mutant NSCLC from ADJUVANT-CTONG 1104 trial

Herein, we characterize the landscape and prognostic significance of the T cell receptor (TCR) repertoire of early-stage non–small cell lung cancer (NSCLC) for patients with an epidermal growth factor receptor (EGFR) mutation. β Chain TCR sequencing was used to characterize the TCR repertoires of pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Cunte, Liu, Si-Yang Maggie, Chen, Yedan, Ou, Qiuxiang, Bao, Hua, Xu, Ling, Zhang, Yikai, Zhong, Wenzhao, Zhou, Qing, Yang, Xue-Ning, Shao, Yang, Wu, Yi-Long, Liu, Si-Yang, Li, Yangqiu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Clinical Investigation 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8765044/ https://www.ncbi.nlm.nih.gov/pubmed/35014626 http://dx.doi.org/10.1172/jci.insight.152631

Ejemplares similares

Poor prognosis of intra‐tumoural TRBV6‐6 variants in EGFR‐mutant NSCLC: Results from the ADJUVANT‐CTONG1104 trial
por: Chen, Cunte, et al.
Publicado: (2022)

Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial
por: Zhong, Wen-Zhao, et al.
Publicado: (2021)

Specific TCR profiles predict clinical outcome of adjuvant EGFR-TKIs for resected EGFR-mutant non-small cell lung cancer
por: Liu, Si-Yang Maggie, et al.
Publicado: (2023)

Identification of TCR Vβ11-2-Dβ1-Jβ1-1 T cell clone specific for WT1 peptides using high-throughput TCRβ gene sequencing
por: Zhang, Yikai, et al.
Publicado: (2019)

Efficacy and Safety of Gefitinib as Third-line Treatment in NSCLC Patients With Activating EGFR Mutations Treated With First-line Gefitinib Followed by Second-line Chemotherapy: A Single-Arm, Prospective, Multicenter Phase II Study (RE-CHALLENGE, CTONG1304)
por: Song, Yong, et al.
Publicado: (2019)

Generation of V α13/β21(+)T cell specific target CML cells by TCR gene transfer
por: Zha, Xianfeng, et al.
Publicado: (2016)

TCR engineered T cells for solid tumor immunotherapy
por: Zhang, Yikai, et al.
Publicado: (2022)

The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706)
por: Zhang, Zhonghan, et al.
Publicado: (2019)

The adjuvant GLA-SE promotes human Tfh cell expansion and emergence of public TCRβ clonotypes
por: Hill, Danika L., et al.
Publicado: (2019)

Comparison of first-generation EGFR-TKIs (gefitinib, erlotinib, and icotinib) as adjuvant therapy in resected NSCLC patients with sensitive EGFR mutations
por: He, Qihua, et al.
Publicado: (2021)

Cost-effectiveness analysis of adjuvant therapy with atezolizumab in Chinese patients with stage IB-IIIA resectable NSCLC after adjuvant chemotherapy
por: Chen, Ping, et al.
Publicado: (2022)

Biphasic function of GSK3β in gefitinib‑resistant NSCLC with or without EGFR mutations
por: Li, Junzhe, et al.
Publicado: (2023)

Gefitinib upregulates death receptor 5 expression to mediate rmhTRAIL-induced apoptosis in Gefitinib-sensitive NSCLC cell line
por: Yan, Dong, et al.
Publicado: (2015)

Characterization of human αβTCR repertoire and discovery of D-D fusion in TCRβ chains
por: Liu, Peipei, et al.
Publicado: (2014)

Fasudil Increased the Sensitivity to Gefitinib in NSCLC by Decreasing Intracellular Lipid Accumulation
por: Liao, Tingting, et al.
Publicado: (2022)

Review and perspective on adjuvant and neoadjuvant immunotherapies in NSCLC
por: Yi, Chengxiang, et al.
Publicado: (2019)

Inhibition of DNA-PK by gefitinib causes synergism between gefitinib and cisplatin in NSCLC
por: Pan, Chi, et al.
Publicado: (2020)

Generation of diffuse large B cell lymphoma-associated antigen-specific Vα6/Vβ13+T cells by TCR gene transfer
por: Yin, Qingsong, et al.
Publicado: (2011)

Pilot study of radiofrequency hyperthermia in combination with gefitinib in gefitinib‐effective patients with advanced NSCLC
por: Qin, Yijia, et al.
Publicado: (2016)

Curcumin Induces EGFR Degradation in Lung Adenocarcinoma and Modulates p38 Activation in Intestine: The Versatile Adjuvant for Gefitinib Therapy
por: Lee, Jen-Yi, et al.
Publicado: (2011)

Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC
por: Qiu, Bin, et al.
Publicado: (2021)

The mechanism of m(6)A methyltransferase METTL3-mediated autophagy in reversing gefitinib resistance in NSCLC cells by β-elemene
por: Liu, Shuiping, et al.
Publicado: (2020)

Combined treatment with N‐acetylcysteine and gefitinib overcomes drug resistance to gefitinib in NSCLC cell line
por: Li, Jun, et al.
Publicado: (2019)

Results and Complications of 1104 Surgeries for Velopharyngeal Insufficiency
por: Hirschberg, Jenő
Publicado: (2012)

1104. Antibiotic Prophylaxis for the Endoscopic Endonasal Approach
por: DeKerlegand, Alaina, et al.
Publicado: (2019)

Update on adjuvant therapy in completely resected NSCLC patients
por: Lim, Jeong Uk, et al.
Publicado: (2021)

Adjuvant and neoadjuvant use of immune checkpoint inhibitors in NSCLC
por: Walia, Anushka, et al.
Publicado: (2023)

Structural basis of the TCR-pHLA complex provides insights into the unconventional recognition of CDR3β in TCR cross-reactivity and alloreactivity
por: San, Dan, et al.
Publicado: (2022)

Inhibition of GPR30 sensitized gefitinib to NSCLC cells via regulation of epithelial-mesenchymal transition
por: Yang, Xiaomin, et al.
Publicado: (2023)

ATM Influences the Efficiency of TCRβ Rearrangement, Subsequent TCRβ-Dependent T Cell Development, and Generation of the Pre-Selection TCRβ CDR3 Repertoire
por: Hathcock, Karen S., et al.
Publicado: (2013)

A Conserved Hydrophobic Patch on Vβ Domains Revealed by TCRβ Chain Crystal Structures: Implications for Pre-TCR Dimerization
por: Zhou, Bo, et al.
Publicado: (2011)

Clinical staging of NSCLC: current evidence and implications for adjuvant chemotherapy
por: Heineman, David J., et al.
Publicado: (2017)

Shorter TCR β-Chains Are Highly Enriched During Thymic Selection and Antigen-Driven Selection
por: Hou, Xianliang, et al.
Publicado: (2019)

FOXO3 mutation predicting gefitinib-induced hepatotoxicity in NSCLC patients through regulation of autophagy
por: Guan, Shaoxing, et al.
Publicado: (2022)

Pre-TCRα and TCRα Are Not Interchangeable Partners of TCRβ during T Lymphocyte Development
por: Borowski, Christine, et al.
Publicado: (2004)

TCR Coexpression Signature Predicts Immunotherapy Resistance in NSCLC
por: Wang, Yuntao, et al.
Publicado: (2022)

Shikonin sensitizes wild-type EGFR NSCLC cells to erlotinib and gefitinib therapy
por: Li, Yang-Ling, et al.
Publicado: (2018)

The importance of genomic predictors for clinical outcome of hematological malignancies
por: Chen, Cunte, et al.
Publicado: (2021)

AURKA upregulation plays a role in fibroblast-reduced gefitinib sensitivity in the NSCLC cell line HCC827
por: CHEN, JIA, et al.
Publicado: (2015)

ABCC10 Plays a Significant Role in the Transport of Gefitinib and Contributes to Acquired Resistance to Gefitinib in NSCLC
por: Zhao, Hongbo, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_5uptiug7o3srgpn29hjpln13dl